Cansino-Vega RA

Language: Spanish
References: 26
Page:
PDF size: 132.74 Kb.

ABSTRACT

No Abstract

REFERENCES

1. Braunwald E. Shattuck Lecture cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–1369.

2. Goodman & Gilman. Farmacoterapia para hipercolesterolemia y dislipidemia. Las bases farmacologicas de la Terapeutica. 11 edicion. Mc Graw hill. 2007. Pp. 948-953

3. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA1998; 279: 1643-1650

4. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106:2041–2042

5. Corsini A, Bellosta S, Baetta R. New insights into the pharmacodynamic and pharmacokinetic properties of statins.Pharmacol Ther 1999;84: 413-428

6. Armitage J. The safety of statins in clinical practice. Lancet 2007; 76: 1027-9

7. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML- 236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 1876; 29: 1346-1348.

8. Corsini A, Raitieri M, Sama MR, Fumangali R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharm Res 1991; 23: 173-180

9. Treasure CB, Klein JL, Weintraub, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterollowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.

10. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz Pet al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-328.

11. Moncada S, Higgs EA. L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.

12. Mason R, Walter M, Jacob R. Effects of HMG-CoA reductase inhibitors on endothelial function. Circulation 2004; 109 suppl II: II-34-41.

13. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27- 36.

14. John S, Schneider MP, Delles C. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J En prensa 2005.

15. Feron O, Dessy C, Desager JP et al. Hydroxy methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.

16. Wassman S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001; 37: 1450-7.

17. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.

18. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: The cholesterol and recurrent events (CARE) study. Circulation 1999; 99: 216-23.

19. The long term intervention with pravastatin in ischemic disease (LIPID) Study group. Prevention of cardiovascular events and deith with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

20. Water DD, Schwartz GG, Olson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or no- Q wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL). Circulation 2002; 106: 1690-1695.

21. Sever PS, Dahlöf B, Poulter NR, Wederls J et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower than average cholesterol concentrations, in the angle svandinavian cardia outcomes trial- lipid lowering arm (ASCOTT-LLA): a multicentre randomized controlled trial. Lancet 2003: 361: 1149-1158.

22. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30:1969-1973.

23. Hennekens C, Hollar D, Eidelman RS et al. Update for primary care providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Med Gen Med 2006; 8: 54.

24. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a metaanalysis of clinical studies. Bone 2007; 40: 1581-7.

25. Fichtenbaum CJ, Gerber JG, Rosenkrantz SL. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16(4): 569-577.

26. Nguyen DH, Taub DD. Targeting lipids to prevent HIV infection.Mol Interv 2004; 4: 318-20.